Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
06:05am, Monday, 22'nd Apr 2024
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
08:30am, Saturday, 20'th Apr 2024
Eli Lilly and Novo Nordisk are two of the big names in healthcare focused on a hot GLP-1 drug market. But there's a drug from a smaller biotech which could also prove to be a big player in this area.
Most people on weight loss drugs are spending less on restaurants and takeout, survey says
08:00am, Saturday, 20'th Apr 2024
The findings add to concerns that GLP-1s could take a bite out of the bottom lines of some of the biggest restaurant companies and packaged food makers.
3 Relatively Safe Growth Stocks You Can Buy and Hold
06:48am, Saturday, 20'th Apr 2024
Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.
Bearish on SMCI & Bullish on LLY, NFLX
01:01pm, Friday, 19'th Apr 2024
Super Micro Computer (SMCI), Eli Lilly (LLY), and Netflix (NFLX) are today's big three stocks. Joel Hawthorne and Ben Lichtenstein discuss how to trade, as well as the technical trends of these names.
Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now
07:30am, Friday, 19'th Apr 2024
When Wall Street tags a stock as a strong buy, it is probably right. Generally speaking, such shares tend to be among the best positioned investments in the market.
Big pharma: cautious optimism ahead of earnings season - analysts
11:35am, Thursday, 18'th Apr 2024
Looking ahead to the pharmaceutical earnings season, UBS expressed cautious optimism when looking at several major names. Notably, Eli Lilly and Co (NYSE:LLY), with a 'buy' rating and a price target
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
09:55am, Thursday, 18'th Apr 2024
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
05:10am, Thursday, 18'th Apr 2024
Tesla's transformation over the past 10 years has made it one of the most valuable stocks on Wall Street. The excitement around a highly promising weight-loss drug has made Eli Lilly a hot buy in rece
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
06:51pm, Wednesday, 17'th Apr 2024
One of the pharmaceutical giant's hotter medications tested well for a new indication. It has already attracted much attention for the molecule being studied, as it's used in two FDA-approved treatmen
Eli Lilly's Chart Gets Another Boost from Obesity Drug
01:59pm, Wednesday, 17'th Apr 2024
From diabetes to heart disease, the obesity drug Zepbound has been shown to have positive effects for other health ailments. Now, the company has a trial pointing to reduced sleep apnea severity.
Eli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea
12:15pm, Wednesday, 17'th Apr 2024
Shares of Eli Lilly (LLY) gained in intraday trading Wednesday after the pharmaceutical firm said a late-stage study found its weight-loss drug, Zepbound, was effective in treating those who are overw
Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says
11:23am, Wednesday, 17'th Apr 2024
The insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
Eli Lilly's weight-loss drug Zepbound might help cure your sleep apnea
11:20am, Wednesday, 17'th Apr 2024
Eli Lilly and Company announced promising results for its weight loss drug Zepbound, indicating its potential as a treatment for sleep apnea. The drug demonstrated effectiveness in reducing the severi
Weight Loss Drug Zepbound May Reduce Sleep Apnea, Eli Lilly Says
10:48am, Wednesday, 17'th Apr 2024
A late-stage trial of Eli Lilly's weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings suggesting p
